Related Experiment Video
Updated: Nov 3, 2025
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.7K
Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment
Shengchang Xin1, Yingyi Wu2, Zhijie Huang3
1State Key Laboratory of Coordination Chemistry Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University Nanjing 210093, Jiangsu, PR China.
Journal of Biomedical Nanotechnology
|June 4, 2021
Summary
Engineered nanovesicles targeting both PD-1 and tumor cells show promise for melanoma treatment. These dual-action nanovesicles effectively inhibit tumor growth and enhance anti-tumor immunity in preclinical models.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Malignant melanoma is aggressive, with poor prognosis due to invasion and metastasis.
- Immune checkpoint inhibitors improve melanoma treatment but face cost and application limitations.
- Novel therapeutic strategies are needed to overcome current treatment challenges.
Purpose of the Study:
- To develop dual-target nanovesicles (NVs) for enhanced melanoma therapy.
- To reactivate T cells by blocking the PD-1/PD-L1 pathway.
- To inhibit tumor cell proliferation using encapsulated siNF90.
Main Methods:
- Designed cellular nanovesicles (NVs) expressing PD-1.
- Encapsulated siNF90 within PD-1 NVs (PD-1 @siNF90 NVs).
- Evaluated therapeutic efficacy in melanoma models, assessing tumor growth, survival, and immune cell infiltration.
Main Results:
- PD-1 @siNF90 NVs inhibited melanoma tumor growth more effectively than PD-1 NVs alone.
- Treatment with PD-1 @siNF90 NVs significantly extended survival time in mice.
- The percentage of CD8+ T cells within tumors was highest following PD-1 @siNF90 NVs treatment, indicating enhanced immune response.
Conclusions:
- PD-1 @siNF90 NVs demonstrate a dual-target therapeutic effect for melanoma.
- This novel nanovesicle system shows potential as a safe and effective treatment for melanoma.
- The approach enhances anti-tumor immunity by combining immune checkpoint blockade with direct tumor cell inhibition.
